Metrion Biosciences Welcomes New CEO Lee Patterson
Metrion Biosciences appoints Lee Patterson as CEO, succeeding Dr. Andrew S., to drive growth and innovation.
Metrion Biosciences, a leader in ion channel screening and preclinical contract research, has appointed Lee Patterson as its new CEO, effective December 2, 2024. With extensive experience in life sciences and contract research organizations, Patterson is set to drive the company's ambitious growth strategy.
Under his leadership, Metrion aims to enhance its specialist services and strengthen its global presence. This transition comes as Dr. Andrew S. steps down after five impactful years as CEO, marking a new chapter for the company’s strategic direction and innovation in the field.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion